NAPLEX COPD Practice Questions with Answers

Concept Explanation

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. In the context of the NAPLEX Prep, understanding COPD involves mastering the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines, which categorize patients based on symptom severity and exacerbation history. Unlike asthma, COPD is generally progressive and not fully reversible. Diagnosis is confirmed by spirometry where a post-bronchodilator ratio of $$\text{FEV}_1 / \text{FVC} < 0.70$$ indicates persistent airflow limitation. Management focuses on symptom relief, reducing exacerbation frequency, and improving exercise tolerance through the use of bronchodilators (beta-2 agonists and muscarinic antagonists) and, in specific cases, inhaled corticosteroids (ICS).

Pharmacotherapy is individualized using the ABCD (or the updated ABE) assessment tool. Long-acting muscarinic antagonists (LAMAs) and long-acting beta-2 agonists (LABAs) are the cornerstones of maintenance therapy. For patients with high blood eosinophil counts or frequent exacerbations despite dual bronchodilation, ICS are added. It is vital to recognize that while NAPLEX Respiratory Pharmacology Practice Questions often cover both asthma and COPD, the use of ICS monotherapy is strictly contraindicated in COPD due to an increased risk of pneumonia and lack of efficacy compared to its role in asthma.

Solved Examples

1. Determining Severity: A patient presents with a post-bronchodilator $$\text{FEV}_1$$ of 45% of the predicted value. According to GOLD grades, what is the severity of their airflow limitation?
   1. Identify the GOLD grading scale for airflow limitation: GOLD 1 (Mild) $\geq 80\%$, GOLD 2 (Moderate) $50-79\%$, GOLD 3 (Severe) $30-49\%$, and GOLD 4 (Very Severe) $< 30\%$.
   2. Compare the patient's value (45%) to the scale.
   3. Conclusion: The patient is classified as GOLD 3 (Severe).
2. Initial Therapy Selection: A patient is diagnosed with COPD. They have a CAT score of 12 and have had 0 hospitalizations for exacerbations in the last year. What is the recommended initial treatment?
   1. Assess the group: High symptoms (CAT $\geq 10$) and low risk (0-1 exacerbations not leading to hospital admission) places the patient in Group B.
   2. Refer to GOLD recommendations for Group B.
   3. Conclusion: Initial therapy should be a long-acting bronchodilator (LAMA or LABA).
3. Handling Exacerbations: A patient with COPD experiences an acute increase in dyspnea and sputum purulence. Which class of medication is first-line for managing this acute exacerbation?
   1. Identify the primary medications for acute symptom management: Short-acting bronchodilators.
   2. Determine the specific agents: Short-acting beta-2 agonists (SABA) like albuterol, with or without short-acting muscarinic antagonists (SAMA) like ipratropium.
   3. Conclusion: SABAs are the preferred initial bronchodilators for acute exacerbations.

Practice Questions

1. A 62-year-old male with COPD (GOLD Group B) is currently taking tiotropium once daily. He still complains of shortness of breath during daily activities. According to GOLD guidelines, what is the most appropriate next step in his maintenance therapy?

2. Which of the following medications is a Long-Acting Muscarinic Antagonist (LAMA) available as a dry powder inhaler (DPI)?

3. Calculate the pack-year smoking history for a patient who smoked 2 packs of cigarettes per day for 15 years and then 1 pack per day for the next 10 years.

4. A patient is prescribed Roflumilast (Daliresp). Which of the following side effects should the pharmacist counsel the patient on, and what is the primary contraindication for this drug?

5. A patient with COPD and a history of two exacerbations in the past year leading to hospitalizations has an eosinophil count of 350 cells/mcL. Which treatment regimen is most appropriate for this patient?

6. Contrast the mechanism of action between Indacaterol and Aclidinium. Which one is more appropriate for a patient with a severe milk protein allergy?

7. A patient is using a Combivent Respimat inhaler. How should the patient be instructed to prime the device if it has not been used for more than 21 days?

8. Which vaccine is specifically recommended by the Centers for Disease Control and Prevention (CDC) for all patients with COPD, regardless of age, to prevent respiratory complications?

9. A pharmacist is reviewing a profile for a patient with COPD who is also being treated for hypertension. Which class of antihypertensives should be used with caution, and why?

10. An elderly patient has difficulty coordinating their breath with the actuation of a Metered Dose Inhaler (MDI). What device modification or alternative would you recommend to improve drug delivery?

Answers & Explanations

1. Answer: Add a LABA (Long-Acting Beta-2 Agonist). For patients in Group B who remain symptomatic on monotherapy, the GOLD guidelines suggest escalating to dual bronchodilation (LAMA + LABA).
2. Answer: Tiotropium (Spiriva HandiHaler) or Umeclidinium (Incruse Ellipta). These are common LAMAs delivered via DPI. Note that Spiriva also comes in a Respimat (SMI) formulation.
3. Answer: 40 pack-years. Use the formula: $$\text{Pack-years} = ( \text{packs per day}) \times ( \text{years smoked})$$. Calculation: $$(2 \times 15) + (1 \times 10) = 30 + 10 = 40 \text{ pack-years}$$.
4. Answer: Weight loss/diarrhea; Contraindicated in moderate-to-severe hepatic impairment. Roflumilast is a PDE-4 inhibitor. Psychiatric effects like depression/suicidality are also concerns.
5. Answer: LAMA + LABA + ICS (Triple Therapy). This patient is in Group E (formerly Group D) due to hospitalizations. An eosinophil count $\geq 300$ cells/mcL is a strong indication for adding an ICS to dual bronchodilator therapy.
6. Answer: Indacaterol is a LABA; Aclidinium is a LAMA. Many DPIs (like some versions of Aclidinium or Umeclidinium) contain lactose, which may have trace milk proteins. Patients with severe milk protein hypersensitivity should use MDIs or SMIs without lactose.
7. Answer: Release three sprays toward the ground. For the Respimat, if it hasn't been used for >21 days, it requires re-priming with three actuations. If unused for 3 days, only one actuation is needed.
8. Answer: Pneumococcal vaccine (PPSV23 and/or PCV20) and Influenza vaccine. Patients with chronic lung disease are at high risk. The CDC also now recommends the RSV vaccine for adults 60+ with chronic respiratory disease.
9. Answer: Non-selective beta-blockers (e.g., Propranolol). These can cause bronchoconstriction by blocking beta-2 receptors in the lungs. Cardioselective beta-blockers (e.g., Metoprolol) are generally preferred if a beta-blocker is necessary.
10. Answer: Use a spacer or valved holding chamber. Using a spacer allows the medication to be suspended in the chamber, removing the need for hand-breath coordination. Alternatively, a Breath-Actuated Inhaler (BAI) or a Dry Powder Inhaler (DPI) could be used.

1. Which of the following is the diagnostic criteria for COPD using spirometry?

• APost-bronchodilator FEV1/FVC ratio &lt; 0.70
• BPre-bronchodilator FEV1/FVC ratio &lt; 0.80
• CPost-bronchodilator FEV1 increase of &gt; 12%
• DTotal Lung Capacity &lt; 80% of predicted

Frequently Asked Questions

What is the difference between Group B and Group E in the GOLD 2023 guidelines?

Group B includes patients with significant symptoms (CAT ≥ 10) but low exacerbation risk (0-1 moderate exacerbations, no hospitalizations). Group E includes all patients with high exacerbation risk (≥ 2 moderate exacerbations or ≥ 1 hospitalization), regardless of their current symptom score.

Can a patient use both a LAMA and a SAMA at the same time?

Generally, it is not recommended to use a LAMA and a SAMA concurrently because they target the same muscarinic receptors. Using both increases the risk of anticholinergic side effects like dry mouth and urinary retention without providing significant additional benefit.

Why is oxygen therapy prescribed for some COPD patients?

Long-term oxygen therapy is indicated for patients with severe resting chronic hypoxemia (PaO2 ≤ 55 mmHg or SaO2 ≤ 88%). It is one of the few interventions proven to increase survival in patients with very severe COPD.

How does Roflumilast help in COPD management?

Roflumilast is a phosphodiesterase-4 inhibitor that reduces inflammation by increasing intracellular cyclic AMP. It is specifically used to reduce the frequency of exacerbations in patients with chronic bronchitis and a history of frequent exacerbations.

Are there any specific inhaler techniques for the Ellipta device?

The Ellipta is a dry powder inhaler that does not require priming or shaking. Patients should be instructed to slide the cover down until they hear a click, breathe out away from the device, and then take a long, deep, steady breath in through the mouthpiece.